Dose-dense chemotherapy for primary breast cancer

Current Opinion in Obstetrics and Gynecology

Volumn 19, Issue 1, 2007, Pages 75-81

  Kümmel, Sherko ^a   Rezai, Mahdi ^b   Kimmig, Rainer ^a   Schmid, Peter ^c  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Department of Senology ^*  (Germany)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Adjuvant therapy; Breast cancer; Dose dense therapy

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; HEMOPOIETIC GROWTH FACTOR; METHOTREXATE; PACLITAXEL;

ADJUVANT THERAPY; ANEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONCEPTUAL FRAMEWORK; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; HEMATOLOGIC DISEASE; HEMATOLOGIC TOXICITY; HUMAN; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 33846231288     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e328011f99a     Document Type: Review

References (19)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-1717.
2. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Ann Oncol 2005; 16:1569-1583.
3. Skipper HE, Schabel FM Jr, Wilcox WS. Experimental evaluation of potential anticancer agents XIII: On the criteria and kinetics associated with 'curability' of experimental leukemia. Cancer Chemother Rep 1964; 35:1-111.
4. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21:976-983.
5. Fisher B, Anderson S, Wickerham DL, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin- cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B22. J Clin Oncol 1997; 15:1858-1869.
6. Fisher B, Anderson S, DeCillis A, et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel project B-25. J Clin Oncol 1999; 17:3374-3388.
7. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986; 70:163-169.
8. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res 1988; 48:7067-7071.
9. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: Ten-year results. J Am Med Assoc 1995; 273:542-547.
10. Bonadonna G, Zambetti M, Moliterni A, et al. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and fluorouracil in operable breast cancer. J Clin Oncol 2004; 22:1614-1620.
11. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense vs. conventionally scheduled and sequential vs. concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21:1431-1439. This study demonstrated at first a significant DFS and OS benefit for patients with node-positive breast cancer for dose-dense chemotherapy.
12. Hudis C, Citron M, Berry D et al. Five-year follow-up of INT C9741: dose-dense (DD) chemotherapy (CRx) is safe and effective. Breast Cancer Res Treat 2005; 94 (Suppl. 1):S20; abstract 41.
13. Venturini M, Del Mastro L, Aitini E, et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst 2005; 97:1724-1733. Both trials (CALGB trial 9741 and the GONG-MIG study) support the concept that dose density has a modest impact on the outcome, particularly among younger patients, HER2-positive patients, and ER-negative patients.
14. Sparano JA, Wang M, Martino S et al. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. Breast Cancer Res Treat 2005; 94 (Suppl. 1): abstract 48.
15. Möbus VJ, Untch M, Du Bois A, et al. Dose-dense sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (≥4 + LN). First results of an AGO-trial. J Clin Oncol 2004; 22 (Suppl.):513.
16. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al. EORTC: Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol 2003; 21:843-850.
17. Kummel S, Krocker J, Kohls A, et al. Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer. Br J Cancer 2006; 94:1237-1244.
18. Untch M, Konecny G, Ditsch N, et al. Dose-dense sequential epirubicin/paclitaxel as preoperative treatment of breast cancer: results of a randomized AGO study. Proc Am Soc Clin Oncol 2002; 21: abstract 133.
19. Green MC, Buzdar AU, Smith T, et al. Weekly (wkly) paclitaxel (P) followed by FAC as primary systemic chemotherapy (PSC) of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3-week (Q 3 wk) P therapy (tx) followed by FAC-final results of a prospective phase III randomized trial. Proc Am Soc Clin Oncol 2002; 21: abstract 135.